[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fwqFSBeb9LRM3Ff8FuiyBfAwFSenuMA3t7V7L_1Mv87M":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":8,"topConditions":11,"upcomingReadouts":31,"phaseBuckets":32,"rows":39},"Melinta Therapeutics, Inc.",[4],32,false,0,12,9235,[12,15,18,20,22,25,27,29],{"name":13,"count":14},"Healthy",5,{"name":16,"count":17},"Abscess",3,{"name":19,"count":17},"Community-acquired Bacterial Pneumonia",{"name":21,"count":17},"Skin and Subcutaneous Tissue Bacterial Infections",{"name":23,"count":24},"Bacterial Skin Diseases",2,{"name":26,"count":24},"Staphylococcal Skin Infections",{"name":28,"count":24},"Wound Infection",{"name":30,"count":24},"Systemic Inflammation",[],[33,34,35,36,37,38],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[40,170,263,314,344,377,403,447,476,498,520,542,561,579,597,615,633,662,680,698,722,740,758,785,803,821],{"intervention":41,"totalTrials":42,"cells":43},"Delafloxacin",10,{"EARLY_PHASE1":44,"PHASE1":46,"PHASE2":92,"PHASE3":117,"PHASE4":166,"NA":168},{"trials":45,"activeCount":8},[],{"trials":47,"activeCount":8},[48,60,71,81],{"nctId":49,"briefTitle":50,"status":51,"phases":52,"primaryCompletion":53,"completion":54,"start":55,"enrollment":56,"conditions":57,"interventions":59},"NCT03534622","Evaluate Safety and Pharmacokinetic To Assess Bronchopulmonary Disposition of Intravenous Delafloxacin in Healthy Adults","COMPLETED",[34],"2018-07-19","2018-07-27","2018-04-30",30,[58],"Pneumonia",[41],{"nctId":61,"briefTitle":62,"status":51,"phases":63,"primaryCompletion":64,"completion":64,"start":65,"enrollment":66,"conditions":67,"interventions":69},"NCT02505997","Study to Evaluate the Effect of Delafloxacin on the Pharmacokinetics of Midazolam in Healthy Subjects",[34],"2015-07","2015-06",22,[68],"VA Drug Interactions",[70,41],"Midazolam",{"nctId":72,"briefTitle":73,"status":51,"phases":74,"primaryCompletion":75,"completion":75,"start":76,"enrollment":77,"conditions":78,"interventions":80},"NCT02245243","Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment",[34],"2015-02","2014-09",40,[79],"Hepatic Impairment",[41],{"nctId":82,"briefTitle":83,"status":84,"phases":85,"primaryCompletion":86,"completion":86,"start":87,"enrollment":88,"conditions":89,"interventions":90},"NCT06612255","A Study Comparing the Bioavailability of a Taste-masked Delafloxacin Powder for Oral Suspension With the Delafloxacin Tablet in Healthy Adults","TERMINATED",[34],"2024-09-11","2024-06-03",16,[13],[41,91],"Delafloxacin Powder",{"trials":93,"activeCount":8},[94,106],{"nctId":95,"briefTitle":96,"status":51,"phases":97,"primaryCompletion":98,"completion":98,"start":99,"enrollment":100,"conditions":101,"interventions":103},"NCT00719810","Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections",[35],"2008-10","2008-06",150,[102,23,26],"Skin Structure Infections",[104,104,105],"delafloxacin","tigecycline",{"nctId":107,"briefTitle":108,"status":51,"phases":109,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":114},"NCT01283581","A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections",[35],"2011-11","2011-01",256,[21],[41,115,116],"Linezolid","Vancomycin",{"trials":118,"activeCount":8},[119,131,143,153],{"nctId":120,"briefTitle":121,"status":51,"phases":122,"primaryCompletion":123,"completion":124,"start":125,"enrollment":126,"conditions":127,"interventions":129},"NCT02679573","Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia",[36],"2018-07-31","2018-08-07","2016-12-14",860,[128],"Community Acquired Bacterial Pneumonia",[41,130,115],"Moxifloxacin",{"nctId":132,"briefTitle":133,"status":84,"phases":134,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":141},"NCT02015637","Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea",[36],"2014-11","2014-12-10","2014-01-23",460,[140],"Gonorrhea",[41,142],"Ceftriaxone",{"nctId":144,"briefTitle":145,"status":51,"phases":146,"primaryCompletion":147,"completion":147,"start":148,"enrollment":149,"conditions":150,"interventions":151},"NCT01811732","Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections",[36],"2014-07","2013-04",660,[21],[41,116,152],"Aztreonam",{"nctId":154,"briefTitle":155,"status":51,"phases":156,"primaryCompletion":157,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":163},"NCT01984684","Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections",[36],"2015-12","2016-01","2014-05",850,[21,162],"Skin Structures and Soft Tissue Infections",[104,164,165],"vancomycin","aztreonam",{"trials":167,"activeCount":8},[],{"trials":169,"activeCount":8},[],{"intervention":171,"totalTrials":172,"cells":173},"solithromycin",8,{"EARLY_PHASE1":174,"PHASE1":176,"PHASE2":199,"PHASE3":220,"PHASE4":259,"NA":261},{"trials":175,"activeCount":8},[],{"trials":177,"activeCount":8},[178,189],{"nctId":179,"briefTitle":180,"status":51,"phases":181,"primaryCompletion":182,"completion":76,"start":183,"enrollment":184,"conditions":185,"interventions":187},"NCT01966055","Pharmacokinetics and Safety of Solithromycin Capsules in Adolescents",[34],"2014-08","2013-12",13,[186],"Bacterial Infections",[188],"Solithromycin",{"nctId":190,"briefTitle":191,"status":51,"phases":192,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":198},"NCT02268279","Pharmacokinetics and Safety of Solithromycin in Adolescents and Children",[34],"2016-10","2015-01",84,[197],"Bacterial Infection",[171],{"trials":200,"activeCount":8},[201,210],{"nctId":202,"briefTitle":203,"status":51,"phases":204,"primaryCompletion":205,"completion":206,"start":157,"enrollment":42,"conditions":207,"interventions":209},"NCT02510599","Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis",[35],"2017-01-27","2017-02-28",[208],"Nonalcoholic Steatohepatitis",[171],{"nctId":211,"briefTitle":212,"status":51,"phases":213,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":219},"NCT01591447","Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea",[35],"2013-06","2012-05",60,[218],"Uncomplicated Urogenital Gonorrhea",[171,188],{"trials":221,"activeCount":8},[222,232,242,251],{"nctId":223,"briefTitle":224,"status":51,"phases":225,"primaryCompletion":226,"completion":226,"start":182,"enrollment":227,"conditions":228,"interventions":229},"NCT02210325","Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea",[36],"2017-02-22",264,[218],[171,230,231],"ceftriaxone","azithromycin",{"nctId":233,"briefTitle":234,"status":84,"phases":235,"primaryCompletion":236,"completion":236,"start":237,"enrollment":238,"conditions":239,"interventions":240},"NCT02605122","Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia",[35,36],"2018-03-21","2016-04",97,[19],[188,241],"Standard of Care",{"nctId":243,"briefTitle":244,"status":51,"phases":245,"primaryCompletion":64,"completion":246,"start":247,"enrollment":248,"conditions":249,"interventions":250},"NCT01968733","Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia",[36],"2015-09","2013-11",863,[19],[188,130],{"nctId":252,"briefTitle":253,"status":51,"phases":254,"primaryCompletion":255,"completion":255,"start":256,"enrollment":126,"conditions":257,"interventions":258},"NCT01756339","Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia",[36],"2014-10","2012-12",[19],[188,130],{"trials":260,"activeCount":8},[],{"trials":262,"activeCount":8},[],{"intervention":264,"totalTrials":265,"cells":266},"Single-Dose IV Oritavancin Diphosphate",4,{"EARLY_PHASE1":267,"PHASE1":269,"PHASE2":287,"PHASE3":289,"PHASE4":310,"NA":312},{"trials":268,"activeCount":8},[],{"trials":270,"activeCount":8},[271,280],{"nctId":272,"briefTitle":273,"status":51,"phases":274,"primaryCompletion":275,"completion":276,"start":277,"enrollment":100,"conditions":278,"interventions":279},"NCT01762839","A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants",[34],"2013-01","2013-02-11","2012-12-27",[13],[264,130],{"nctId":281,"briefTitle":282,"status":51,"phases":283,"primaryCompletion":284,"completion":284,"start":275,"enrollment":88,"conditions":285,"interventions":286},"NCT01784536","Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers",[34],"2013-03",[13],[264],{"trials":288,"activeCount":8},[],{"trials":290,"activeCount":8},[291,303],{"nctId":292,"briefTitle":293,"status":51,"phases":294,"primaryCompletion":295,"completion":296,"start":297,"enrollment":298,"conditions":299,"interventions":301},"NCT01252719","Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)",[36],"2012-10","2012-11-30","2010-12",968,[28,16,30,300],"Cellulitis",[264,302],"IV Vancomycin",{"nctId":304,"briefTitle":305,"status":51,"phases":306,"primaryCompletion":214,"completion":214,"start":297,"enrollment":307,"conditions":308,"interventions":309},"NCT01252732","Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection",[36],1019,[28,16,30,300],[264,302],{"trials":311,"activeCount":8},[],{"trials":313,"activeCount":8},[],{"intervention":130,"totalTrials":265,"cells":315},{"EARLY_PHASE1":316,"PHASE1":318,"PHASE2":324,"PHASE3":326,"PHASE4":340,"NA":342},{"trials":317,"activeCount":8},[],{"trials":319,"activeCount":8},[320],{"nctId":272,"briefTitle":273,"status":51,"phases":321,"primaryCompletion":275,"completion":276,"start":277,"enrollment":100,"conditions":322,"interventions":323},[34],[13],[264,130],{"trials":325,"activeCount":8},[],{"trials":327,"activeCount":8},[328,332,336],{"nctId":120,"briefTitle":121,"status":51,"phases":329,"primaryCompletion":123,"completion":124,"start":125,"enrollment":126,"conditions":330,"interventions":331},[36],[128],[41,130,115],{"nctId":243,"briefTitle":244,"status":51,"phases":333,"primaryCompletion":64,"completion":246,"start":247,"enrollment":248,"conditions":334,"interventions":335},[36],[19],[188,130],{"nctId":252,"briefTitle":253,"status":51,"phases":337,"primaryCompletion":255,"completion":255,"start":256,"enrollment":126,"conditions":338,"interventions":339},[36],[19],[188,130],{"trials":341,"activeCount":8},[],{"trials":343,"activeCount":8},[],{"intervention":115,"totalTrials":17,"cells":345},{"EARLY_PHASE1":346,"PHASE1":348,"PHASE2":350,"PHASE3":367,"PHASE4":373,"NA":375},{"trials":347,"activeCount":8},[],{"trials":349,"activeCount":8},[],{"trials":351,"activeCount":8},[352,363],{"nctId":353,"briefTitle":354,"status":51,"phases":355,"primaryCompletion":356,"completion":356,"start":357,"enrollment":100,"conditions":358,"interventions":361},"NCT00646958","Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections",[35],"2008-04","2007-12",[359,23,26,360,16],"Infectious Skin Diseases","Streptococcal Infections",[362,362,115],"Radezolid",{"nctId":107,"briefTitle":108,"status":51,"phases":364,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":365,"interventions":366},[35],[21],[41,115,116],{"trials":368,"activeCount":8},[369],{"nctId":120,"briefTitle":121,"status":51,"phases":370,"primaryCompletion":123,"completion":124,"start":125,"enrollment":126,"conditions":371,"interventions":372},[36],[128],[41,130,115],{"trials":374,"activeCount":8},[],{"trials":376,"activeCount":8},[],{"intervention":116,"totalTrials":17,"cells":378},{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":389,"PHASE4":399,"NA":401},{"trials":380,"activeCount":8},[],{"trials":382,"activeCount":8},[],{"trials":384,"activeCount":8},[385],{"nctId":107,"briefTitle":108,"status":51,"phases":386,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":387,"interventions":388},[35],[21],[41,115,116],{"trials":390,"activeCount":8},[391,395],{"nctId":144,"briefTitle":145,"status":51,"phases":392,"primaryCompletion":147,"completion":147,"start":148,"enrollment":149,"conditions":393,"interventions":394},[36],[21],[41,116,152],{"nctId":154,"briefTitle":155,"status":51,"phases":396,"primaryCompletion":157,"completion":158,"start":159,"enrollment":160,"conditions":397,"interventions":398},[36],[21,162],[104,164,165],{"trials":400,"activeCount":8},[],{"trials":402,"activeCount":8},[],{"intervention":404,"totalTrials":24,"cells":405},"Meropenem-Vaborbactam",{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":412,"PHASE4":443,"NA":445},{"trials":407,"activeCount":8},[],{"trials":409,"activeCount":8},[],{"trials":411,"activeCount":8},[],{"trials":413,"activeCount":8},[414,428],{"nctId":415,"briefTitle":416,"status":51,"phases":417,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":421,"interventions":424},"NCT02166476","Efficacy\u002FSafety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP",[36],"2016-04-28","2014-11-20",550,[422,423],"Urinary Tract Infection Complicated","Acute Pyelonephritis",[404,425,426,427],"Piperacillin-Tazobactam","Levofloxacin","Saline",{"nctId":429,"briefTitle":430,"status":431,"phases":432,"primaryCompletion":433,"completion":434,"start":435,"enrollment":8,"conditions":436,"interventions":441},"NCT03006679","A Study of Meropenem-Vaborbactam Versus Piperacillin\u002FTazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia","WITHDRAWN",[36],"2020-06","2020-12","2018-08",[437,438,439,440],"Hospital-Acquired Bacterial Pneumonia","Ventilator-Associated Bacterial Pneumonia","Hospital-Acquired Pneumonia","Ventilator-Associated Pneumonia",[404,442],"Piperacillin\u002FTazobactam",{"trials":444,"activeCount":8},[],{"trials":446,"activeCount":8},[],{"intervention":426,"totalTrials":24,"cells":448},{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":453,"PHASE3":466,"PHASE4":472,"NA":474},{"trials":450,"activeCount":8},[],{"trials":452,"activeCount":8},[],{"trials":454,"activeCount":8},[455],{"nctId":456,"briefTitle":457,"status":51,"phases":458,"primaryCompletion":459,"completion":459,"start":460,"enrollment":461,"conditions":462,"interventions":464},"NCT01168713","Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia",[35],"2011-07","2010-08",132,[463],"Community-Acquired Bacterial Pneumonia",[426,465],"CEM-101",{"trials":467,"activeCount":8},[468],{"nctId":415,"briefTitle":416,"status":51,"phases":469,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":470,"interventions":471},[36],[422,423],[404,425,426,427],{"trials":473,"activeCount":8},[],{"trials":475,"activeCount":8},[],{"intervention":302,"totalTrials":24,"cells":477},{"EARLY_PHASE1":478,"PHASE1":480,"PHASE2":482,"PHASE3":484,"PHASE4":494,"NA":496},{"trials":479,"activeCount":8},[],{"trials":481,"activeCount":8},[],{"trials":483,"activeCount":8},[],{"trials":485,"activeCount":8},[486,490],{"nctId":292,"briefTitle":293,"status":51,"phases":487,"primaryCompletion":295,"completion":296,"start":297,"enrollment":298,"conditions":488,"interventions":489},[36],[28,16,30,300],[264,302],{"nctId":304,"briefTitle":305,"status":51,"phases":491,"primaryCompletion":214,"completion":214,"start":297,"enrollment":307,"conditions":492,"interventions":493},[36],[28,16,30,300],[264,302],{"trials":495,"activeCount":8},[],{"trials":497,"activeCount":8},[],{"intervention":230,"totalTrials":24,"cells":499},{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":504,"PHASE3":506,"PHASE4":516,"NA":518},{"trials":501,"activeCount":8},[],{"trials":503,"activeCount":8},[],{"trials":505,"activeCount":8},[],{"trials":507,"activeCount":8},[508,512],{"nctId":223,"briefTitle":224,"status":51,"phases":509,"primaryCompletion":226,"completion":226,"start":182,"enrollment":227,"conditions":510,"interventions":511},[36],[218],[171,230,231],{"nctId":132,"briefTitle":133,"status":84,"phases":513,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":514,"interventions":515},[36],[140],[41,142],{"trials":517,"activeCount":8},[],{"trials":519,"activeCount":8},[],{"intervention":152,"totalTrials":24,"cells":521},{"EARLY_PHASE1":522,"PHASE1":524,"PHASE2":526,"PHASE3":528,"PHASE4":538,"NA":540},{"trials":523,"activeCount":8},[],{"trials":525,"activeCount":8},[],{"trials":527,"activeCount":8},[],{"trials":529,"activeCount":8},[530,534],{"nctId":144,"briefTitle":145,"status":51,"phases":531,"primaryCompletion":147,"completion":147,"start":148,"enrollment":149,"conditions":532,"interventions":533},[36],[21],[41,116,152],{"nctId":154,"briefTitle":155,"status":51,"phases":535,"primaryCompletion":157,"completion":158,"start":159,"enrollment":160,"conditions":536,"interventions":537},[36],[21,162],[104,164,165],{"trials":539,"activeCount":8},[],{"trials":541,"activeCount":8},[],{"intervention":425,"totalTrials":543,"cells":544},1,{"EARLY_PHASE1":545,"PHASE1":547,"PHASE2":549,"PHASE3":551,"PHASE4":557,"NA":559},{"trials":546,"activeCount":8},[],{"trials":548,"activeCount":8},[],{"trials":550,"activeCount":8},[],{"trials":552,"activeCount":8},[553],{"nctId":415,"briefTitle":416,"status":51,"phases":554,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":555,"interventions":556},[36],[422,423],[404,425,426,427],{"trials":558,"activeCount":8},[],{"trials":560,"activeCount":8},[],{"intervention":427,"totalTrials":543,"cells":562},{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":567,"PHASE3":569,"PHASE4":575,"NA":577},{"trials":564,"activeCount":8},[],{"trials":566,"activeCount":8},[],{"trials":568,"activeCount":8},[],{"trials":570,"activeCount":8},[571],{"nctId":415,"briefTitle":416,"status":51,"phases":572,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":573,"interventions":574},[36],[422,423],[404,425,426,427],{"trials":576,"activeCount":8},[],{"trials":578,"activeCount":8},[],{"intervention":442,"totalTrials":543,"cells":580},{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":587,"PHASE4":593,"NA":595},{"trials":582,"activeCount":8},[],{"trials":584,"activeCount":8},[],{"trials":586,"activeCount":8},[],{"trials":588,"activeCount":8},[589],{"nctId":429,"briefTitle":430,"status":431,"phases":590,"primaryCompletion":433,"completion":434,"start":435,"enrollment":8,"conditions":591,"interventions":592},[36],[437,438,439,440],[404,442],{"trials":594,"activeCount":8},[],{"trials":596,"activeCount":8},[],{"intervention":231,"totalTrials":543,"cells":598},{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":603,"PHASE3":605,"PHASE4":611,"NA":613},{"trials":600,"activeCount":8},[],{"trials":602,"activeCount":8},[],{"trials":604,"activeCount":8},[],{"trials":606,"activeCount":8},[607],{"nctId":223,"briefTitle":224,"status":51,"phases":608,"primaryCompletion":226,"completion":226,"start":182,"enrollment":227,"conditions":609,"interventions":610},[36],[218],[171,230,231],{"trials":612,"activeCount":8},[],{"trials":614,"activeCount":8},[],{"intervention":241,"totalTrials":543,"cells":616},{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":621,"PHASE3":623,"PHASE4":629,"NA":631},{"trials":618,"activeCount":8},[],{"trials":620,"activeCount":8},[],{"trials":622,"activeCount":8},[],{"trials":624,"activeCount":8},[625],{"nctId":233,"briefTitle":234,"status":84,"phases":626,"primaryCompletion":236,"completion":236,"start":237,"enrollment":238,"conditions":627,"interventions":628},[35,36],[19],[188,241],{"trials":630,"activeCount":8},[],{"trials":632,"activeCount":8},[],{"intervention":362,"totalTrials":24,"cells":634},{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":639,"PHASE3":656,"PHASE4":658,"NA":660},{"trials":636,"activeCount":8},[],{"trials":638,"activeCount":8},[],{"trials":640,"activeCount":8},[641,652],{"nctId":642,"briefTitle":643,"status":51,"phases":644,"primaryCompletion":645,"completion":646,"start":647,"enrollment":648,"conditions":649,"interventions":651},"NCT00640926","Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia",[35],"2009-03","2009-04","2007-10",158,[650],"Community-Acquired Pneumonia (CAP)",[362,362,362],{"nctId":353,"briefTitle":354,"status":51,"phases":653,"primaryCompletion":356,"completion":356,"start":357,"enrollment":100,"conditions":654,"interventions":655},[35],[359,23,26,360,16],[362,362,115],{"trials":657,"activeCount":8},[],{"trials":659,"activeCount":8},[],{"trials":661,"activeCount":8},[],{"intervention":105,"totalTrials":543,"cells":663},{"EARLY_PHASE1":664,"PHASE1":666,"PHASE2":668,"PHASE3":674,"PHASE4":676,"NA":678},{"trials":665,"activeCount":8},[],{"trials":667,"activeCount":8},[],{"trials":669,"activeCount":8},[670],{"nctId":95,"briefTitle":96,"status":51,"phases":671,"primaryCompletion":98,"completion":98,"start":99,"enrollment":100,"conditions":672,"interventions":673},[35],[102,23,26],[104,104,105],{"trials":675,"activeCount":8},[],{"trials":677,"activeCount":8},[],{"trials":679,"activeCount":8},[],{"intervention":465,"totalTrials":543,"cells":681},{"EARLY_PHASE1":682,"PHASE1":684,"PHASE2":686,"PHASE3":692,"PHASE4":694,"NA":696},{"trials":683,"activeCount":8},[],{"trials":685,"activeCount":8},[],{"trials":687,"activeCount":8},[688],{"nctId":456,"briefTitle":457,"status":51,"phases":689,"primaryCompletion":459,"completion":459,"start":460,"enrollment":461,"conditions":690,"interventions":691},[35],[463],[426,465],{"trials":693,"activeCount":8},[],{"trials":695,"activeCount":8},[],{"trials":697,"activeCount":8},[],{"intervention":699,"totalTrials":543,"cells":700},"Single-Dose IV Oritavancin Diphosphate and Warfarin",{"EARLY_PHASE1":701,"PHASE1":703,"PHASE2":714,"PHASE3":716,"PHASE4":718,"NA":720},{"trials":702,"activeCount":8},[],{"trials":704,"activeCount":8},[705],{"nctId":706,"briefTitle":707,"status":51,"phases":708,"primaryCompletion":246,"completion":246,"start":709,"enrollment":710,"conditions":711,"interventions":712},"NCT02340988","Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects",[34],"2015-04",36,[13],[699,713],"Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose",{"trials":715,"activeCount":8},[],{"trials":717,"activeCount":8},[],{"trials":719,"activeCount":8},[],{"trials":721,"activeCount":8},[],{"intervention":713,"totalTrials":543,"cells":723},{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":732,"PHASE3":734,"PHASE4":736,"NA":738},{"trials":725,"activeCount":8},[],{"trials":727,"activeCount":8},[728],{"nctId":706,"briefTitle":707,"status":51,"phases":729,"primaryCompletion":246,"completion":246,"start":709,"enrollment":710,"conditions":730,"interventions":731},[34],[13],[699,713],{"trials":733,"activeCount":8},[],{"trials":735,"activeCount":8},[],{"trials":737,"activeCount":8},[],{"trials":739,"activeCount":8},[],{"intervention":70,"totalTrials":543,"cells":741},{"EARLY_PHASE1":742,"PHASE1":744,"PHASE2":750,"PHASE3":752,"PHASE4":754,"NA":756},{"trials":743,"activeCount":8},[],{"trials":745,"activeCount":8},[746],{"nctId":61,"briefTitle":62,"status":51,"phases":747,"primaryCompletion":64,"completion":64,"start":65,"enrollment":66,"conditions":748,"interventions":749},[34],[68],[70,41],{"trials":751,"activeCount":8},[],{"trials":753,"activeCount":8},[],{"trials":755,"activeCount":8},[],{"trials":757,"activeCount":8},[],{"intervention":759,"totalTrials":543,"cells":760},"Current Formulation of Oritavancin",{"EARLY_PHASE1":761,"PHASE1":763,"PHASE2":777,"PHASE3":779,"PHASE4":781,"NA":783},{"trials":762,"activeCount":8},[],{"trials":764,"activeCount":8},[765],{"nctId":766,"briefTitle":767,"status":51,"phases":768,"primaryCompletion":769,"completion":770,"start":771,"enrollment":772,"conditions":773,"interventions":775},"NCT03873987","Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients",[34],"2019-08-27","2019-09-04","2019-07-16",102,[774],"Acute Bacterial Skin and Skin Structure Infection",[759,776],"Kimyrsa",{"trials":778,"activeCount":8},[],{"trials":780,"activeCount":8},[],{"trials":782,"activeCount":8},[],{"trials":784,"activeCount":8},[],{"intervention":776,"totalTrials":543,"cells":786},{"EARLY_PHASE1":787,"PHASE1":789,"PHASE2":795,"PHASE3":797,"PHASE4":799,"NA":801},{"trials":788,"activeCount":8},[],{"trials":790,"activeCount":8},[791],{"nctId":766,"briefTitle":767,"status":51,"phases":792,"primaryCompletion":769,"completion":770,"start":771,"enrollment":772,"conditions":793,"interventions":794},[34],[774],[759,776],{"trials":796,"activeCount":8},[],{"trials":798,"activeCount":8},[],{"trials":800,"activeCount":8},[],{"trials":802,"activeCount":8},[],{"intervention":91,"totalTrials":543,"cells":804},{"EARLY_PHASE1":805,"PHASE1":807,"PHASE2":813,"PHASE3":815,"PHASE4":817,"NA":819},{"trials":806,"activeCount":8},[],{"trials":808,"activeCount":8},[809],{"nctId":82,"briefTitle":83,"status":84,"phases":810,"primaryCompletion":86,"completion":86,"start":87,"enrollment":88,"conditions":811,"interventions":812},[34],[13],[41,91],{"trials":814,"activeCount":8},[],{"trials":816,"activeCount":8},[],{"trials":818,"activeCount":8},[],{"trials":820,"activeCount":8},[],{"intervention":822,"totalTrials":17,"cells":823},"Oritavancin",{"EARLY_PHASE1":824,"PHASE1":826,"PHASE2":845,"PHASE3":847,"PHASE4":849,"NA":851},{"trials":825,"activeCount":8},[],{"trials":827,"activeCount":8},[828,837],{"nctId":829,"briefTitle":830,"status":51,"phases":831,"primaryCompletion":832,"completion":832,"start":194,"enrollment":833,"conditions":834,"interventions":836},"NCT02357524","Oritavancin on the Results of Multiple Coagulation Tests in Healthy Volunteers",[34],"2015-03",20,[835],"Healthy Volunteers",[822],{"nctId":838,"briefTitle":839,"status":51,"phases":840,"primaryCompletion":841,"completion":841,"start":65,"enrollment":842,"conditions":843,"interventions":844},"NCT02470702","Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects",[34],"2015-10",14,[13],[822],{"trials":846,"activeCount":8},[],{"trials":848,"activeCount":8},[],{"trials":850,"activeCount":8},[],{"trials":852,"activeCount":8},[853],{"nctId":854,"briefTitle":855,"status":51,"phases":856,"primaryCompletion":857,"completion":858,"start":859,"enrollment":860,"conditions":861,"interventions":863},"NCT03159403","A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting",[],"2018-02-15","2018-03-08","2017-04-12",325,[862],"Gram-Positive Bacterial Infections",[822]]